🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Calgary
Clinical trial register · Canada

Clinical Trials in Calgary, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6540 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:55 UTC
6540
Studies in scope
all four open statuses
3515
Recruiting now
open to new participants
887
Lead sponsors
across recruiting studies
Top sites
Toronto 117 Montreal 107 Calgary 62 Vancouver 54 Edmonton 52
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Calgary148 AstraZeneca62 AbbVie37 Janssen Research & Development, LLC30 National Cancer Institute (NCI)27 Clear sponsor filter
Site location
Toronto117 Montreal107 Calgary62 Vancouver54 Edmonton52
All 74 locations
Target enrolment
to

Trials with a site in Calgary

62 of 6540 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Recruiting
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
NCT07624305Renal Insufficiency, Chronic
DrugsBalcinrenone/dapagliflozin·Dapagliflozin
AstraZeneca
Phase 3
2,800
Calgary, Edmonton, Winnipeg, Halifax, Brampton, Greater Sudbury, London, Mississauga
2026-09-01
Not yet open
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)
DrugsASCT·AZD0120·Melphalan·Lenalidomide
AstraZeneca
Phase 3
750
Calgary
2026-08-25
Recruiting
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
NCT07776509Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
DrugLenbelintide
AstraZeneca
Phase 3
500
Calgary, Surrey, Vancouver, Guelph, Hamilton, Stouffville, Toronto, Joliette
2026-08-24
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
7,000
Calgary, Edmonton, Vancouver, Winnipeg, Saint John, London, Scarborough Village, Toronto
2026-08-21
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
DrugLenbelintide
AstraZeneca
Phase 3
1,500
Calgary, Vancouver, Moncton, Truro, Hamilton, Markham, North York, Sarnia
2026-08-20
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
DrugLenbelintide
AstraZeneca
Phase 3
2,500
Calgary, New Westminster, Surrey, Victoria, Moncton, Truro, Brampton, Guelph
2026-08-19
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Calgary, Hamilton, Toronto
2026-07-24
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
DrugsRilvegostomig·Enfortumab Vedotin·Datopotamab deruxtecan·Opdivo
AstraZeneca
Phase 3
915
Calgary, Abbotsford British Columbia, Barrie, Hamilton, Kingston, London, Mississauga, Montreal
2026-07-16
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
DrugElecoglipron
AstraZeneca
Phase 3
4,500
Calgary, Vancouver, Victoria, Moncton, Truro, Brampton, Hamilton, Niagara Falls
2026-06-29
Recruiting
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978Newly Diagnosed Multiple Myeloma
DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab
AstraZeneca
Phase 3
750
Calgary, Vancouver, Halifax, Ottawa, Montreal, Sherbrooke
2026-06-26
Active, closed
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugsCliramitug·Eplontersen
AstraZeneca
Phase 2
326
Calgary, Vancouver, Halifax, London, Toronto, Montreal
2026-06-11
Recruiting
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
NCT07509151Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
DrugSurovatamig
AstraZeneca
Phase 3
420
Calgary, Vancouver, Halifax, Hamilton, Toronto, Montreal, Québec
2026-05-05
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
NCT07430306Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
245
Calgary, Richmond, Winnipeg, Hamilton, Toronto
2026-04-13
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
DrugsDarzalex·AZD0120·Velcade·Carfilzomib
AstraZeneca
Phase 3
508
Calgary, Vancouver, Toronto, Montreal
2026-02-23
Recruiting
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
NCT07336446Prostate Cancer
DrugSaruparib
AstraZeneca
Phase 1/2
300
Calgary, Vancouver
2026-01-27
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Calgary, Vancouver, Halifax, Barrie, Toronto, Montreal, Québec
2025-12-04
Recruiting
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
NCT07215585Large B-cell Lymphoma
DrugsR-mini-CHOP·Surovatamig
AstraZeneca
Phase 3
420
Calgary, Victoria, Hamilton, Ottawa
2025-11-11
Recruiting
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization
DrugAZD0292
AstraZeneca
Phase 2
435
Calgary, Vancouver, Ajax, Stoney Creek, Québec, Saint-Charles-Borromée, Trois-Rivières
2025-11-06
Recruiting
LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada
NCT07143110Lung Neoplasms
AstraZeneca
Observational
60,000
Calgary, Toronto
2025-08-20
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
DrugBaxdrostat
AstraZeneca
Phase 3
250
Calgary, Ottawa, Toronto, Montreal
2025-08-07
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/Prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Calgary, Abbotsford British Columbia, Vancouver, Barrie, Brampton, London, Toronto, Chicoutimi
2025-08-06
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsTaxotere·Rilvegostomig·Paraplatin·Taxol
AstraZeneca
Phase 3
600
Calgary, Edmonton, Winnipeg, Halifax, London, Toronto, Montreal, Québec
2025-03-27
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
DrugTezepelumab
AstraZeneca
Phase 3
990
Calgary, Vancouver, Ajax, Burlington, Scarborough Village, Toronto, Winchester, Windsor
2025-03-18
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Calgary, Sherwood Park, Abbotsford British Columbia, Moncton, Saint John, St. John's, Halifax, Sydney
2025-03-14
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil
AstraZeneca
Phase 3
840
Calgary, Edmonton, Winnipeg, Barrie, Brampton, Hamilton, Toronto, Chicoutimi
2025-03-01
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250B-cell Malignancies
DrugAZD5492
AstraZeneca
Phase 1/2
174
Calgary, Toronto, Montreal
2024-09-18
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Calgary, Montreal
2024-06-20
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
100
Calgary, Vancouver, Toronto
2024-03-14
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,000
Calgary, Sherwood Park, Kelowna, Richmond, Winnipeg, Sydney, Ajax, Guelph
2024-02-21
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Calgary, Edmonton, Halifax, London
2023-12-20
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
DrugVolrustomig
AstraZeneca
Phase 3
1,145
Calgary, Edmonton, Kelowna, Kingston, London, Toronto, Chicoutimi, Montreal
2023-12-14
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate
AstraZeneca
Phase 3
1,898
Calgary, Abbotsford British Columbia, Kelowna, Vancouver, Kingston, Mississauga, Newmarket, Ottawa
2023-11-21
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsDatopotamab deruxtecan·Epirubicin·Xeloda·Olaparib
AstraZeneca
Phase 3
1,902
Calgary, Vancouver, Barrie, London, Oshawa, Toronto, Lévis, Montreal
2023-11-14
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Calgary, Toronto, Montreal, Québec
2023-11-08
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
895
Calgary, Edmonton, Winnipeg, Halifax, Barrie, Oshawa, Toronto, Lévis
2023-10-24
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Calgary, Edmonton, Kelowna, North Vancouver, Barrie, Greater Sudbury, Kingston, Thunder Bay
2023-10-05
Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
NCT06355934ATTR Amyloidosis
AstraZeneca
Observational
52,121
Calgary
2023-08-21
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
Calgary, Kelowna, Winnipeg, Barrie, Ottawa, Sault Ste. Marie, Toronto, Windsor
2023-03-31
Active, closed
A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.
NCT05637112Systemic Lupus Erythematosus
AstraZeneca
Observational
551
Calgary, Winnipeg, Hamilton, Orillia, Toronto, Rimouski, Sherbrooke, Ste-Foy
2023-02-27
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
DrugTozorakimab
AstraZeneca
Phase 3
3,527
Calgary, New Westminster, Winnipeg, Brampton, Ottawa, Toronto, Lévis, Montreal
2022-12-13
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
DrugsEribulin·Datopotamab deruxtecan·Nab-paclitaxel·Capecitabine
AstraZeneca
Phase 3
644
Calgary, Barrie, Hamilton, Ottawa, Toronto, Greenfield Park, Montreal, Québec
2022-05-16
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
DrugsTremelimumab·Lenvatinib·Durvalumab
AstraZeneca
Phase 3
760
Calgary, Halifax, Kingston, Ottawa, Toronto, Montreal
2022-03-28
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
DrugsDomvanalimab·Durvalumab
AstraZeneca
Phase 3
791
Calgary, Kelowna, Laval, Montreal
2022-02-18
Active, closed
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090Papillary Renal Cell Carcinoma
DrugsSavolitinib·Sunitinib·Durvalumab
AstraZeneca
Phase 3
148
Calgary, Montreal
2021-10-28
Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
DrugsPalacaparib·Saruparib·Rilvegostomig
AstraZeneca
Phase 1/2
460
Calgary, Vancouver, Ottawa, Toronto, Montreal
2021-10-18
Active, closed
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Ribociclib·Abemaciclib
AstraZeneca
Phase 3
315
Calgary, Vancouver, Ottawa, Lévis, Montreal, Québec
2021-06-30
Active, closed
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715Breast Cancer; HER2-positive; Metastatic
DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab
AstraZeneca
Phase 3
1,157
Calgary, Halifax, Barrie, Kitchener, Newmarket, North York, Toronto, Montreal
2021-04-26
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel
AstraZeneca
Phase 3
866
Calgary, Edmonton, Vancouver, Toronto, London, Montreal, Sherbrooke
2020-07-24
Active, closed
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853Hormone-Sensitive Prostate Cancer
DrugsZytiga·Capivasertib·Abiraterone acetate
AstraZeneca
Phase 3
1,012
Calgary, Edmonton, Kelowna, Vancouver, Brampton, Oshawa, Toronto, Montreal
2020-07-13
Active, closed
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200Endometrial Neoplasms
DrugsOlaparib·Durvalumab·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
805
Calgary, Toronto, Montreal
2020-05-05
Active, closed
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
NCT04157348Eosinophilic Granulomatous Vasculitis
DrugsBenralizumab·Mepolizumab
AstraZeneca
Phase 3
140
Calgary, Hamilton, Toronto
2019-10-29
Active, closed
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300Asthma
DrugBenralizumab
AstraZeneca
Phase 4
75
Calgary
2019-10-08
Active, closed
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486Non-Small Cell Lung Cancer
DrugsPemetrexed/Cisplatin·Pemetrexed/Carboplatin·Osimertinib
AstraZeneca
Phase 3
587
Calgary, Edmonton, Toronto
2019-07-02
Recruiting
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
NCT03813407Hyperkalaemia
DrugPumitamig
AstraZeneca
Phase 3
140
Calgary, Edmonton, Vancouver, Montreal
2019-04-02
Active, closed
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
NCT03778229Carcinoma
DrugsSavolitinib·Osimertinib
AstraZeneca
Phase 2
367
Calgary, Edmonton, Newmarket, North York, Toronto
2019-01-09
Active, closed
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03737643Advanced Ovarian Cancer
DrugsOlaparib·Durvalumab·Paclitaxel·Bevacizumab
AstraZeneca
Phase 3
1,407
Calgary, Barrie, Greater Sudbury, Toronto, Montreal, Québec, Rimouski
2019-01-04
Active, closed
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
NCT03732820Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone acetate·Olaparib
AstraZeneca
Phase 3
895
Calgary, Edmonton, Kelowna, Halifax, London, Toronto, Greenfield Park, Montreal
2018-10-31
Active, closed
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin
AstraZeneca
Phase 3
1,246
Calgary, Edmonton, Vancouver, Hamilton, Ottawa, Toronto, Montreal
2018-09-27
Active, closed
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03330847Metastatic Triple Negative Breast Cancer
DrugCeralasertib
AstraZeneca
Phase 2
273
Calgary, Kelowna, Ottawa, Toronto
2018-03-07
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
DrugsSorafenib·Tremelimumab·Durvalumab
AstraZeneca
Phase 3
1,324
Calgary, Edmonton, Hamilton, Kingston, London, Toronto, Montreal, Québec
2017-10-11
Active, closed
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241Urothelial Cancer
DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin
AstraZeneca
Phase 3
1,126
Calgary, Edmonton, Kelowna, Vancouver, Halifax, Hamilton, Newmarket, Oshawa
2015-11-02
Active, closed
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
NCT02143466Advanced Non Small Cell Lung Cancer
DrugsSavolitinib·Selumetinib·Osimertinib·Durvalumab
AstraZeneca
Phase 1
344
Calgary, Edmonton
2014-08-05
Rows per page Showing 1–62 of 62
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-canada/city/calgary

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,540 studies in total at the last sync on 26 Sep 2026, 19:55 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 62 of those studies with a site in Calgary that also match the filters currently applied.

How many clinical trials are recruiting in Calgary?

34 of the 62 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:55 UTC sync. A further 1 have not yet opened recruitment, 27 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Calgary), 62 studies
PhaseStudiesRecruitingShare
Phase 3492779%
Observational436.5%
Phase 2416.5%
Phase 1/2334.8%
Phase 1101.6%
Phase 4101.6%

Most active sponsors

Lead sponsors with the most studies (Calgary)
Lead sponsorStudiesRecruiting
AstraZeneca6234
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.